Clinical trials: Cancer of Bile Duct
Bile Duct Stricture, Malignancy
Performance of FISH for the Diagnosis of Malignant Biliary Strictures in Thai Patients
Fluorescence in situ hybridization (FISH) has improved the diagnostic performance of cytology for evaluation of malignant biliary strictures in the US and Europe.
- Trial name
- NCT02442167
- Volunteers
- 101 people
- Sponsor
- Mayo Clinic
Anal Cancer, Colorectal Cancer
Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer
RATIONALE: Gathering information about patients' quality of life during radiation therapy for cancer may help doctors plan the best treatment.
- Conditions
- Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00836992
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Mayo Clinic
Choledochal Cyst
A Longitudinal Cohort Study on the Changes of Physiological Mechanisms in Children After Biliary Tract Reconstruction
Through observational studies, the long-term changes in liver function, metabolic state, immune response and other aspects of children after biliary tract reconstruction during their growth process were systematically explored.
- Trial name
- NCT07530354
- Where
- 3 sites in China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Wuhan Children's Hospital
Liver Transplantation, Hepatitis
Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation
The purpose of the study is to test the safety and effectiveness of IDN-6556 in preventing liver damage that normally occurs when livers are transported before being transplanted and in the immediate post-transplant period.
- Conditions
- Liver Transplantation, Hepatitis, Cholestasis, Carcinoma, Hepatocellular
- Trial name
- NCT00080236
- Testing
- IDN-6556
- Where
- 13 sites in United States, Germany
- Volunteers
- 99 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Neoplasms, Non-Neoplastic
AI Guidance for Biopsy in Suspected Cholangiocarcinoma
Digital single-operator cholangioscopy (DSOC) has emerged as a medical advance with an important role in the evaluation of indeterminate biliary lesions.
- Conditions
- Neoplasms, Non-Neoplastic, Bile Duct Neoplasms, Bile Duct Lesions
- Trial name
- NCT05374122
- Testing
- DSOC with AI biopsy guidance, DSOC biopsy without AI guidance
- Where
- Ecuador
- Volunteers
- 48 people
- Sponsor
- Instituto Ecuatoriano de Enfermedades Digestivas
Pancreas Neoplasms, Bile Duct Diseases
Intra-ductal Confocal Endomicroscopy for Characterization of Pancreas and Bile Duct Tumor
The endomicroscopy is an adaptation of traditional optical microscopy in the digestive endoscopy. Furthermore, with the integration of a miniaturized laser confocal microscope to a videoendoscope, it's possible to study the…
- Trial name
- EMID (NCT00930410)
- Testing
- Endoscopic Retrograde Cholangio-Pancreatography (ERCP)
- Where
- 2 sites in France, Monaco
- Volunteers
- 50 people
- Sponsor
- Institut Paoli-Calmettes
Gastric Cancer, Pancreatic Cancer
Use of the EnLightTM and LightPathTM Imaging Systems in Gastrointestinal Tumour Surgery
This study will evaluate the performance of the EnLightTM and LightPathTM Imaging Systems in detecting tumour lesions in patients with gastric, pancreas, bile duct or duodenal cancer.
- Conditions
- Gastric Cancer, Pancreatic Cancer, Bile Duct Cancer, Duodenal Cancer
- Trial name
- CLIO (NCT02446379)
- Testing
- The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose, EnLightTM, LightPathTM Imaging System
- Where
- Hungary
- Sponsor
- Lightpoint Medical Limited
Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma
Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
This phase II trial is studying how well giving sorafenib tosylate together with erlotinib hydrochloride works in treating patients with locally advanced, unresectable, or metastatic gallbladder cancer or cholangiocarcinoma.
- Conditions
- Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma, Gallbladder Adenocarcinoma With Squamous Metaplasia, Hilar Cholangiocarcinoma
- Trial name
- NCT01093222
- Testing
- Erlotinib Hydrochloride, Sorafenib Tosylate
- Where
- 141 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Cholangiocarcinoma, Biliary Stricture
Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma
Successful palliation of biliary obstruction is the main goal for reducing morbidity and mortality in patients with biliary disease and biliary obstruction related to cholangiocarcinoma.
- Conditions
- Cholangiocarcinoma, Biliary Stricture, Biliary Obstruction, Bile Duct Cancer
- Trial name
- NCT01755013
- Testing
- Photodynamic Therapy
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Weill Medical College of Cornell University
Cholangiocarcinoma, Bile Duct Neoplasms
Suprapapillary Metal Stent vs. Routine Transpapillary Drainage in Malignant Hilar Biliary Obstruction (SMART-B Trial)
Malignant hilar biliary obstruction is a condition in which the bile ducts near the liver become blocked due to cancer. This blockage can lead to jaundice (yellowing of the skin and eyes), itching, infection, and impaired liver…
- Conditions
- Cholangiocarcinoma, Bile Duct Neoplasms, Malignant Biliary Obstruction
- Trial name
- SMART-B (NCT07558304)
- Testing
- Percutaneous transpapillary internal-external biliary drainage, Percutaneous suprapapillary biliary drainage with self-expanding metal stent
- Where
- 2 sites in Brazil
- Volunteers
- 84 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Liver Cancer, Neoplasm Metastasis
A Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG®-1 in Tumor Patients With Hepatic Metastases
The primary objective of study CT 4003 is to assess the behavior of EndoTAG®-1 in the body (making a so-called pharmacokinetic profile). Therefore, the course of the drug in the body is examined, i.e.
- Trial name
- NCT00542048
- Testing
- EndoTAG®-1
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- MediGene
Bile Duct Cancer, Chemotherapy Effect
DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer
To assess the effect of AZD6738 and Durvalumab combination or AZD6738 and Olaparib combination in biliary tract cancer patients who have failed to 1st-line chemotherapy.
- Trial name
- NCT04298021
- Testing
- AZD6738, Durvalumab, Olaparib
- Where
- South Korea
- Volunteers
- 74 people
- Sponsor
- Seoul National University Hospital
Hilar Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma
Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma
The goal of this observational cohort study is to assess the yield of preoperative endoscopic ultrasound focussed on lymph nodes in patients with presumed resectable perihilar (pCCA), intrahepatic (iCCA) or mid-common bile duct…
- Conditions
- Hilar Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Common Bile Duct Neoplasms, Cholangiocarcinoma
- Trial name
- POELH-II (NCT05678218)
- Testing
- Endoscopic Ultrasound registration
- Where
- 7 sites in Belgium, Netherlands
- Volunteers
- 245 people
- Sponsor
- Erasmus Medical Center
Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
This phase II trial is studying how well bortezomib works as first-line systemic therapy in treating patients with unresectable locally advanced or metastatic adenocarcinoma (cancer) of the bile duct or gallbladder.
- Conditions
- Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Advanced Adult Primary Liver Cancer, Gastrointestinal Cancer
- Trial name
- NCT00085410
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder
Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery
RATIONALE: Stent placement may help reduce symptoms caused by the tumor. Photodynamic therapy uses a drug, such as porfimer sodium, that becomes active when it is exposed to a certain kind of light.
- Conditions
- Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
- Trial name
- NCT00253617
- Testing
- porfimer sodium, adjuvant therapy, laser therapy
- Where
- 2 sites in United States, Canada
- Sponsor
- Jonsson Comprehensive Cancer Center
Biliary Tract Cancer, Cholangiocarcinoma
Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer
This study is going to test the ability to successfully obtain results from certain personalized tests for patients with biliary tract cancers that are able to be surgically removed.
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer, Intrahepatic Cholangiocarcinoma
- Trial name
- NCT04561453
- Testing
- Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Washington
Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder
Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors
This phase II trial is studying how well giving bevacizumab together with erlotinib hydrochloride works in treating patients with metastatic or unresectable biliary tumors.
- Conditions
- Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Gastrointestinal Cancer, Recurrent Extrahepatic Bile Duct Cancer
- Trial name
- NCT00356889
- Testing
- erlotinib hydrochloride, bevacizumab
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Common Bile Duct Diseases
A Prospective Clinical Study Using an Artery-first Intermediate Approach in Robot-assisted Pancreaticoduodenectomy
Pancreaticoduodenectomy, as a standard surgical procedure for malignant tumors of the head of the pancreas, ampulla and distal common bile duct, has brought the hope of clinical cure for these diseases.In the whole surgical…
- Conditions
- Pancreatic Cancer, Common Bile Duct Diseases, Periampullary Carcinoma
- Trial name
- NCT05660915
- Testing
- Intermediate approach, Standard approach
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital of University of South China
Pancreatic Adenocarcinoma, Cholangiocarcinoma
The Future Management of Patients With Neoplasms of the Gastro-intestinal Tract
The aim of the present study is to research histological and molecular markers in patients with neoplasia of the gastrointestinal tract.
- Conditions
- Pancreatic Adenocarcinoma, Cholangiocarcinoma, Colon Cancer
- Trial name
- SOCRATE (NCT06728358)
- Testing
- Molecular analyses
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Gallbladder Carcinoma, Metastatic Cholangiocarcinoma
Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
This randomized phase II trial studies how well atezolizumab with or without cobimetinib works in treating patients with bile duct cancer that has spread to other places in the body (metastatic) and cannot be removed by surgery…
- Conditions
- Gallbladder Carcinoma, Metastatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT03201458
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 41 sites in United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)